Artrya Limited (ASX:AYA): How Does Salix AI Support Coronary CT Assessment?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Artrya Limited (ASX:AYA): How Does Salix AI Support Coronary CT Assessment?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Artrya (ASX:AYA) develops AI-based coronary diagnostic support software.
Salix assists trained clinicians with assessment of coronary CT images.
The Salix Coronary Anatomy product is listed on Australia’s therapeutic goods register.
The Salix Central USA product has received US regulatory clearance.

Artrya Limited (ASX:AYA) develops artificial intelligence-based software designed to support clinicians analysing coronary computed tomography images for signs of coronary artery disease. Its shares were quoted at AUD 3.47 on 12 November 2026, down 3.07% during the session. The company’s Salix software platform, its stated indications for use and the regulatory status of particular products provide the central context for understanding its commercial activity. Product clearances define permitted use; they do not independently establish patient outcomes or future sales.

Salix and Coronary Image Analysis

Artrya (ASX:AYA) focuses on software that processes coronary computed tomography angiography, often abbreviated CCTA. These images allow clinicians to assess blood vessels supplying the heart. The Salix platform offers tools for visualising and measuring coronary arteries and assessing plaques, narrowing and calcification. The software is intended for suitably trained medical professionals who retain responsibility for clinical judgement. It is an adjunct to the review of original images and patient history rather than an autonomous diagnosis. This distinction matters when discussing the intended role of artificial intelligence in medical decision-making.

Regulatory Position and Product Availability

Artrya (ASX:AYA) states on its official product information that Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods. The company also identifies regulatory clearance in the United States for the Salix Central USA product. These descriptions refer to specific products and jurisdictions; they should not be interpreted as a blanket clearance for every Salix function or market. Availability in other regions depends on the applicable regulatory position. Product claims also need to remain within the scope of intended use, Training requirements and the documentation accompanying each authorised version.

Clinical Workflow and Commercial Considerations

Artrya (ASX:AYA) describes its Business as cardiac image analysis technology, with particular emphasis on coronary plaque assessment. In practical use, software must fit hospital or clinic processes involving scan acquisition, interpretation and reporting. Adoption may depend on compatibility with clinical information systems, staff training, data security and the degree to which the product improves an established workflow. A commercial agreement, pilot or product evaluation is not automatically equivalent to recurring recognised revenue. Without a verified contemporary financial figure, no revenue, Earnings or cash-balance estimate is assumed here.

Risks in Medical Artificial Intelligence

Medical image software operates within clinical, regulatory and Cybersecurity constraints. Artrya (ASX:AYA) must address product performance, validation, appropriate deployment and changes in regulatory requirements. Measurement tools can be affected by the underlying quality and resolution of medical images, and their output requires qualified interpretation. Commercial execution also involves hospital procurement timelines, software integration and ongoing customer support. Regulatory clearance is an important prerequisite in regulated markets, but it is distinct from broad clinical adoption and financial profitability.

What to Watch Next

Subsequent Artrya (ASX:AYA) announcements can clarify the commercial availability of each Salix module, customer implementation activity, any additional regulatory decisions and published financial results. Investors may monitor recognised receipts, operating cash expenditure and the scale of the clinical customer base when official figures are released. Particular attention should be paid to whether reported milestones concern approval, installation, contracted activity or completed sales, as each represents a different stage in the product lifecycle.

Key Insights

Artrya (ASX:AYA) is developing coronary CT analysis software intended to assist, not replace, trained clinicians. Its publicly described Australian and US regulatory positions relate to specified products. Future company reporting on product deployment, approvals and financial performance can provide a clearer measure of commercial progression without extending claims beyond the stated indications for use.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.